Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Lord Abbett & CO. LLC

Lord Abbett & CO. LLC trimmed its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 47.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 667,881 shares of the company’s stock after selling 599,922 shares during the period. Lord Abbett & CO. LLC owned 1.13% of Janux Therapeutics worth $18,033,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in Janux Therapeutics by 1,574.0% during the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company’s stock valued at $45,000 after purchasing an additional 1,574 shares during the period. US Bancorp DE boosted its stake in Janux Therapeutics by 2,402.9% during the 1st quarter. US Bancorp DE now owns 1,727 shares of the company’s stock valued at $47,000 after purchasing an additional 1,658 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after acquiring an additional 442 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Janux Therapeutics in the 4th quarter worth approximately $59,000. Finally, FNY Investment Advisers LLC lifted its stake in shares of Janux Therapeutics by 6,928.6% in the 1st quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company’s stock worth $66,000 after acquiring an additional 2,425 shares during the period. 75.39% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Raymond James Financial started coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They issued an “outperform” rating and a $65.00 price target for the company. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Janux Therapeutics has an average rating of “Buy” and an average price target of $91.89.

Janux Therapeutics Stock Up 0.6%

Shares of JANX opened at $25.11 on Friday. The company’s fifty day moving average is $24.61 and its 200-day moving average is $28.42. Janux Therapeutics, Inc. has a 12 month low of $21.97 and a 12 month high of $71.71. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -13.95 and a beta of 2.86.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.07). As a group, research analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.